

**"5th International Conference on Thrombosis and
Hemostasis Issues in Cancer"**

Stresa (Lake Maggiore), Italy, April 23-25, 2010

PRELIMINARY PROGRAM

Friday – April 23th, 2010

08.30-10.00 Congress Secretariat Opening: Registration

10.00-13.00 Satellite Symposia

Congress Opening

14.00-14.30 Opening Remarks: Conference Chairmen

14.30-15.15 Plenary Lecture: *Role of vWF and other platelet ligands in tumor biology* - D. Wagner (USA)

15.15-15.45 Coffee Break

15.45-17.30 Plenary Session 1

RISK FACTORS FOR THROMBOSIS IN CANCER

Chairs: M. Prins (Netherlands), P.M. Mannucci (Italy)

15.45-16.10 *Risk stratification and models* - A. Khorana (USA)

16.10-16.35 *Antitumor and supportive therapy and thrombosis* – A. Lee (Canada)

16.35-17.00 *Tests predictive of thrombosis in cancer* - I. Pabinger (Germany)

17.00-17.30 *Oral Communications*

17.30-18.30 DEBATE

Thromboprophylaxis during chemotherapy

Chair: C. Francis (USA)

NO: M. Levine (USA) - *YES*: G. Agnelli (Italy)

19.30 Welcome Cocktail

Saturday – April 24th, 2010

08.30-10.30 Plenary Session 2

THROMBOPROPHYLAXIS IN CANCER PATIENTS

Chairs: P. Prandoni (Italy), TBA

08.30-08.55 *Thromboprophylaxis for medical patients* – A.T. Cohen (UK)

08.55-09.20 *Thromboprophylaxis for cancer surgery* – A. Kakkar (UK)

09.20-09.45 *New anticoagulants for patients with cancer* – J. Weitz (Canada)

09.45-10.30 *Oral Communications*

10.30-11.00 Coffee Break

11.00-13.00 Simultaneous Session 1 & 2

Simultaneous Session 1: BIOLOGY OF BLOOD COAGULATION IN CANCER

Chairs: H.A. Liebman (USA), J. Degen (USA)

11.00-11.25 *Signaling and Procoagulant Contributions of Tissue Factor to Cancer Progression* – W. Ruf (USA)

11.25-11.50 *Fibrinolytic Proteins, Platelets and Tumor Spread* – J. Palumbo (USA)

11.50-12.15 *Activation of Clotting Proteins by Tumor Genetic Programs* – J.W. Rak (Canada)

12.15-13.00 *Oral Communications*

Simultaneous Session 2: BLEEDING AND CANCER

Chairs: M. Levi (Netherlands), A. Federici (Italy)

11.00-11.25 *Open issues in Acute Promyelocytic Leukemia* - M. Sanz (Spain)

11.25-11.50 *Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact* – F. Rodeghiero, F. Elice (Italy)

11.50-12.15 *Bleeding complications associated with anticoagulant therapy in patients with cancer* – M. Monreal (Spain)

12.15-13.00 *Oral Communications*

13.00-14.00 Lunch

14.00-16.00 Plenary Session 3

ANTITUMOR PROPERTIES OF ANTICOAGULANTS

Chairs: J. Harenberg (Germany), G. Palareti (Italy)

14.00-14.10 *Update on the predictive value of D-dimer in patients with idiopathic VTE* – G. Palareti (Italy)

14.10-14.35 *Experimental approaches and new drugs* - L. Borsig (Switzerland)

14.35-15.00 *Heparanase procoagulant effects and inhibition by heparins* – Y. Nadir (Israel)

15.00-15.25 *Anticoagulants in mouse models* – C. J. Van Noorden (Netherlands)

15.25-15.50 *Clinical evidence for use of LMWH as adjuvant therapy in patients with cancer* – H.R. Büller (Netherlands)

15.50-16.10 *Oral Communications*

16.10-16.30 Coffee Break

16.30-18.30 Simultaneous Session 3 & 4

Simultaneous Session 3: MICROPARTICLES IN TUMOR GROWTH

Chairs: F.R. Rickles (USA), F. Dignat-George (France)

16.30-16.55 *Membrane microparticles in VTE and cancer: Actors or Artifacts* – N. Key (USA)

16.55-17.20 *Microparticles in cancer disease and progression* - J-M. Freyssinet (France)

17.20-17.45 *Predictive value of TF-bearing microparticles in VTE/cancer patients* – J.I. Zwicker (USA)

17.45-18.30 *Oral Communications*

Simultaneous Session 4: THROMBOTIC COMPLICATIONS OF CANCER

Chairs: R. White (USA), TBA

16.30-16.55 *Population based studies* – M.B. Donati (Italy)

16.55-17.20 *VTE in acute leukemia, lymphoma and myeloma* – T. Wun (USA)

17.20-17.45 *The risk of cancer in OAT patients* - V. Pengo (Italy)

17.45-18.30 *Oral Communications*

20.00 Social Dinner

Sunday – April 25th, 2010

08.30-10.30 Plenary Session 4

UPDATED GUIDELINES FOR PREVENTION AND TREATMENT OF VTE IN CANCER

Chairs: A. Falanga (Italy), TBA

08.30-08.55 *French guidelines* – D. Farge-Bancel (France)

08.55-09.20 *ESMO guidelines* – R. Labianca (Italy)

09.20-09.45 *ASCO guidelines* – G. Lyman (USA)

09.45-10.10 *NCCN guidelines* – M. Streiff (USA)

10.10-10.30 *Unresolved issues* – G. Lyman (USA)

10.30-11.00 Coffee Break

11.00-13.00 Simultaneous Session 5 & 6

Simultaneous Session 5: TARGETING HEMOSTATIC SYSTEM AS THERAPY FOR CANCER

Chairs: H. ten Cate (Netherlands), P.M. Sandset (Norway)

11.00-11.25 *Targeting tumor vessel anionic phospholipids: experimental and clinical studies* - P.E. Thorpe (USA)

11.25-11.50 *The role of activated protein C in tumor metastasis* – G.L. Van Sluis (Netherlands)

11.50-12.15 *Vascular targeting with TF constructs* – W.E. Berdel (Germany)

12.15-13.00 *Oral Communications*

Simultaneous Session 6: GENDER- AND AGE-RELATED ISSUES

Chairs: U. Nowak-Göttl (Germany), B. Brenner (Israel)

11.00-11.25 *Thrombohemorrhagic complications in children with hemato-oncological diseases* – M.C. Putti (Italy)

11.25-11.50 *Epidemiology and risk factors for VTE in female cancer* - N. Kuderer (USA)

11.50-12.15 *Thrombosis in male cancer* – J. Beyer (Germany)

12.15-13.00 *Oral Communications*

13.00-14.00 Lunch

14.00-16.00 Poster Discussion Sessions

16.00-17.00 Meeting Closed

20.00 Farewell Party